We found that, compared to the IL-2 only treated group, CHDMAPP and IL-2 co-treatment significantly increased the proportion of circulating T cells that were γ9+ pre-infection (P<0.01) and post infection (P<0.001) (Figure 6A). The gene discussed is IL2; the disease is infection.